Two steps ahead: the method for spotting bargains before the market
A forum debates how to spot structural needs before the market does: obsolete medical equipment, Autodesk, ROIC and the VIX as a compass.
English · Original discussion in Spanish · Published
Two steps ahead: the method for spotting bargains before the market
One summer, an investor reads a news story about obsolete medical equipment in Spain and has a lightbulb moment: there is a structural problem, and someone will have to solve it. That is how a method begins — one that is not about guessing the next hot stock, but about positioning yourself two steps ahead of the crowd. The idea, repeated on a stock market forum for 49 days, is simple: spot a real need, identify who can meet it, and check whether the price already reflects it. The result is a list of usual suspects —Siemens Healthineers, GE Healthcare, Philips— and an uncomfortable question: are they cheap, or simply beaten down?
The case that started it all: medical equipment on its last legs
The spark was a news story about Spain's hospital equipment fleet: one third of it is obsolete. The reasoning then extended to Europe: an ageing population, a renewal deficit, machines that will need replacing in one, three or five years. Three companies dominate the business: Siemens Healthineers, GE Healthcare and Philips. All trade below their all-time highs, all pay a dividend, and all have direct exposure to the sector. The question hanging in the air is whether the market has already priced in the problem or whether, on the contrary, there is room for structural demand to translate into profits.
But the initial enthusiasm collides with the reality of public spending. A participant with experience in the healthcare sector sums it up: "In the public health system the budget is usually very tight and equipment replacement is slow". There are hospitals that cannibalise parts from retired machines to keep equipment running with no replacements available. The conclusion: the demand exists, but the timetable is set not by the market but by budgets.
Beyond the big names: reagents, maintenance and captive contracts
The business is not just in selling the machine. A laboratory professional points out that the real goldmine is reagents and maintenance. Companies sell the equipment cheap in tenders and then squeeze the customer with consumables and service contracts. That is Roche's model, but it also applies to radiology: plates first, maintenance contracts later. That recurring revenue stream is what creates long-term value, not the one-off sales spike.
The conversation drifts towards companies that are not listed. There are huge manufacturers outside the stock market, such as Trumpf, spanning several sectors. The conclusion is that the investment universe is broader than the index, but also harder to access. For the retail investor, the liquid options boil down to the three big names, with the caveat that the real business may be in private hands.
The pivot to software: Autodesk and the AI suspicion
The focus shifts when someone mentions Autodesk. The 3D design software company falls sharply despite posting record profits. The market antiestéticars that artificial intelligence could cannibalise its business. One participant sums it up: "More and more alternative software keeps coming out, but it remains the Microsoft of the industry". The question is whether the recurring subscription revenue and its dominance in architecture and engineering are enough to keep the moat intact.
The analysis gets sharper. Recurring revenue, low capex and low capital intensity are virtues. But the five-year CAGR is negative and the share price has spent six years trading between 200 and 300 dollars. The key question is not whether the company is good, but whether the current price offers a margin of safety. The answer, for now, is that it is not clear. The advice that gets repeated: the company must perform well and the price must be below the value. Without the second condition, it is not investing, it is gambling.
The method expands: ROIC, VIX and opportunities falling from the sky
The conversation moves on to metrics. ROIC gains ground over net profit or EPS. But a doubt arises: in growth companies, ROIC can be low at first because investment takes time to mature. The answer is that context matters: a mature business is not the same as one that is building its future.
The VIX, the antiestéticar gauge, also comes up. The idea is simple: when it is high, there are opportunities. Cases are mentioned such as Intuit, which drops 10% after posting record results. The explanation offered is that the market prices in expectations, not just facts. The sarracena: "Whether Intuit falls 10% or 80%, I couldn't care less. What matters to me is the company's real value".
The opportunity nobody sees: batteries, regulation and electrifiable sectors
The focus widens to the EU battery regulation. There are companies that benefit from exemptions: manufacturers of ATEX equipment, electric toys, medical devices, wearables. The list includes names such as Pepperl+Fuchs, Mattel, LEGO, Dexcom, Samsung, Logitech. The idea is that regulation creates winners and losers, and anticipating it is part of the method.
Pentair is also mentioned — water and pool management, trading at 50 euros with a P/E of 15.54. The central valuation calculation comes out at 75 euros, leaving room to manoeuvre if there is another dip. It does not pay a big dividend, but the trade is speculative with a small tip while you wait. The method repeats itself: detect, analyse, wait for the price.
The two-steps-ahead method is not a magic formula. It is a discipline: seeing what others do not see, checking whether the price cooperates, and accepting that the market can take years to prove you right. The final question is not which company to buy, but what it is truly worth. And that, in a market driven by headlines, remains the hardest part.
One summer, an investor reads a news story about obsolete medical equipment in Spain and has a lightbulb moment: there is a structural problem, and someone will have to solve it. That is how a method begins — one that is not about guessing the next hot stock, but about positioning yourself two steps ahead of the crowd. The idea, repeated on a stock market forum for 49 days, is simple: spot a real need, identify who can meet it, and check whether the price already reflects it. The result is a list of usual suspects —Siemens Healthineers, GE Healthcare, Philips— and an uncomfortable question: are they cheap, or simply beaten down?
The case that started it all: medical equipment on its last legs
The spark was a news story about Spain's hospital equipment fleet: one third of it is obsolete. The reasoning then extended to Europe: an ageing population, a renewal deficit, machines that will need replacing in one, three or five years. Three companies dominate the business: Siemens Healthineers, GE Healthcare and Philips. All trade below their all-time highs, all pay a dividend, and all have direct exposure to the sector. The question hanging in the air is whether the market has already priced in the problem or whether, on the contrary, there is room for structural demand to translate into profits.
But the initial enthusiasm collides with the reality of public spending. A participant with experience in the healthcare sector sums it up: "In the public health system the budget is usually very tight and equipment replacement is slow". There are hospitals that cannibalise parts from retired machines to keep equipment running with no replacements available. The conclusion: the demand exists, but the timetable is set not by the market but by budgets.
Beyond the big names: reagents, maintenance and captive contracts
The business is not just in selling the machine. A laboratory professional points out that the real goldmine is reagents and maintenance. Companies sell the equipment cheap in tenders and then squeeze the customer with consumables and service contracts. That is Roche's model, but it also applies to radiology: plates first, maintenance contracts later. That recurring revenue stream is what creates long-term value, not the one-off sales spike.
The conversation drifts towards companies that are not listed. There are huge manufacturers outside the stock market, such as Trumpf, spanning several sectors. The conclusion is that the investment universe is broader than the index, but also harder to access. For the retail investor, the liquid options boil down to the three big names, with the caveat that the real business may be in private hands.
The pivot to software: Autodesk and the AI suspicion
The focus shifts when someone mentions Autodesk. The 3D design software company falls sharply despite posting record profits. The market antiestéticars that artificial intelligence could cannibalise its business. One participant sums it up: "More and more alternative software keeps coming out, but it remains the Microsoft of the industry". The question is whether the recurring subscription revenue and its dominance in architecture and engineering are enough to keep the moat intact.
The analysis gets sharper. Recurring revenue, low capex and low capital intensity are virtues. But the five-year CAGR is negative and the share price has spent six years trading between 200 and 300 dollars. The key question is not whether the company is good, but whether the current price offers a margin of safety. The answer, for now, is that it is not clear. The advice that gets repeated: the company must perform well and the price must be below the value. Without the second condition, it is not investing, it is gambling.
The method expands: ROIC, VIX and opportunities falling from the sky
The conversation moves on to metrics. ROIC gains ground over net profit or EPS. But a doubt arises: in growth companies, ROIC can be low at first because investment takes time to mature. The answer is that context matters: a mature business is not the same as one that is building its future.
The VIX, the antiestéticar gauge, also comes up. The idea is simple: when it is high, there are opportunities. Cases are mentioned such as Intuit, which drops 10% after posting record results. The explanation offered is that the market prices in expectations, not just facts. The sarracena: "Whether Intuit falls 10% or 80%, I couldn't care less. What matters to me is the company's real value".
The opportunity nobody sees: batteries, regulation and electrifiable sectors
The focus widens to the EU battery regulation. There are companies that benefit from exemptions: manufacturers of ATEX equipment, electric toys, medical devices, wearables. The list includes names such as Pepperl+Fuchs, Mattel, LEGO, Dexcom, Samsung, Logitech. The idea is that regulation creates winners and losers, and anticipating it is part of the method.
Pentair is also mentioned — water and pool management, trading at 50 euros with a P/E of 15.54. The central valuation calculation comes out at 75 euros, leaving room to manoeuvre if there is another dip. It does not pay a big dividend, but the trade is speculative with a small tip while you wait. The method repeats itself: detect, analyse, wait for the price.
The two-steps-ahead method is not a magic formula. It is a discipline: seeing what others do not see, checking whether the price cooperates, and accepting that the market can take years to prove you right. The final question is not which company to buy, but what it is truly worth. And that, in a market driven by headlines, remains the hardest part.
Also available in: Deutsch
Summary of a discussion on Burbuja.info - Foro de economía, actualidad y política., translated from Spanish and reviewed before publication. Read the full discussion (88 replies).
More summaries
-
Precious metals forum devolves into bans and accusations
A thread on gold and silver investment turns into mass blocking and mutual accusations among users, with no verified evidence.
-
Spain: Offshore Schemes to Shield Assets Before Divorce
Setting up offshore entities in Nevis or Belize costs around €2,000 but risks criminal asset concealment charges in Spain.
-
Spanish bond soars 200 basis points even as the ECB keeps buying
Spain's ten-year bond yield has jumped 200 basis points while the ECB is still buying. Germany has gone from -0.5% to 1% and the US is above 3%. It looks ugly.
-
Andorrano jeweller: silver ounces wrapped in cling film
999 fine silver ounces sent wrapped in transparent film when an order doesn't fill a full tube: the clash between competitive prices and packaging that tarnishes the coins.
-
WH Smith: deep-value candidate or falling knife?
WH Smith trades at 0.45 times sales and 3 times EBITDA as the market punishes its restructuring and the Iran conflict. Opportunity or value trap?
-
TelexFREE: the scheme that promised $400 a month
TelexFREE promised $400 a month for posting ads. The investment: $1,425. The reality: withdrawals blocked until reaching $300 and an investigation in Brazil.